473795-47-0

Usage

Uses

Used in Pharmaceutical Synthesis:
1-Azabicyclo[3.2.2]nonan-3-one(9CI) serves as a crucial precursor in the creation of compounds with antiviral, antibacterial, and antifungal properties. Its incorporation into the synthesis process aids in the development of new pharmaceuticals that target a range of infectious diseases.
Used in Organic Synthesis:
As a valuable tool in organic synthesis, 1-Azabicyclo[3.2.2]nonan-3-one(9CI) is used to construct complex molecular structures. Its unique reactivity allows for the formation of new chemical bonds and the creation of a diverse array of organic compounds.
Used in Drug Development:
1-Azabicyclo[3.2.2]nonan-3-one(9CI)'s biological activities and chemical properties make it an important target for research in drug development. It is instrumental in the exploration of new therapeutic agents and the enhancement of existing pharmaceuticals, contributing to advancements in the pharmaceutical industry.
Used in Research and Development:
1-Azabicyclo[3.2.2]nonan-3-one(9CI) is also utilized in research and development settings to study its potential applications and to understand its interactions with other molecules. This research is vital for uncovering new uses and optimizing the compound's role in pharmaceutical and chemical applications.

Upstream product

• 1009629-89-3 1-chloro-3-piperidi-4-ylacetone trifluoroacetate 
• 1580440-22-7 tert-butyl 4-(3-hydroxy-2-oxopropyl)piperidine-1-carboxylate 
• 1580440-21-6 tert-butyl 4-(3-(benzyloxy)-2-oxopropylidene)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 206989-54-0 tert-butyl 4-(2-oxopropyl)piperidine-1-carboxylate 
• 473795-40-3 1-(N-tert-butoxycarbonylpiperidin-4-ylidene)propan-2-one 
• 473795-43-6 tert-Butyl 4-(3-Bromo-2-Oxopropyl)Piperidine-1-Carboxylate 
• 473795-46-9 1-bromo-3-(piperidin-4-yl)acetone trifluoroacetate 

Relevant academic research and scientific papers

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

Preparation of novel azabicyclic amines and α7 nicotinic acetylcholine receptor activity of derived aryl amides

(Chemical Equation Presented) Three new azabicyclic amines, namely exo-3-amino-1-azabicyclo[3.2.1]octane, 3-amino-1-azabicyclo-[3.2.2]nonane and exo-6-amino-8-azabicyclo[3.2.1]octane, have been designed and prepared as isosteres of 3-aminoquinuclidine. Ar

1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY

The invention provides compounds of Formula (I), wherein Azabicyclo is Formula (I, II, III, IV, V, VI, VII); W is Formula (m); where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which α7 is known to be involved.

Substituted azabicyclic moieties for the treatment of disease

The invention provides compounds of Formula I: 1wherein m1 is 0 or 1; m2 is 1 or 2; R1 is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl; R2 is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl, provided that when m1 is 1 at least one of R1 and R2 is —H; or a pharmaceutically acceptable salt, pharmaceutical composition, a pure enantiomer or racemic mixture thereof. The invention also provides a method for treating a disease or condition in a mammal, wherein the α7 nicotinic acetylcholine receptor is implicated and for treating diseases where there is a sensory-gating deficit in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of Formula I. These compounds may be in the form of pharmaceutical salts or compositions, and may be in pure enantiomeric form or may be racemic mixtures.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: 1wherein Azabicyclo is 2These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.

Azabicyclic compounds for the treatment of disease

The invention provides compounds of Formula I: wherein Azabicyclo is W is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1-2 substitutents independently selected from R3. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat diseases or conditions in which α7 is known to be involved.

Substituted-aryl compounds for treatment of disease

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals to treat diseases or conditions in which α7 is known to be involved.

1-azabicyclo[3.2.2]nonan-3-amine derivatives

The present invention relates to novel 1-azabicyclo[3.2.2]nonan-3-amine derivatives of the formula STR1 wherein R1, R2, R3, R4, R5 are each independently selected from hydrogen, fluorine, chlorine, br